Literature DB >> 14528094

Extracapsular radiation dose distribution after permanent prostate brachytherapy.

Gregory S Merrick1, Wayne M Butler, Kent E Wallner, Lauren R Burden, Jackee E Dougherty.   

Abstract

The physical extent of the radiation therapy dose delivered to the periprostatic region was evaluated in 26 consecutive patients with low-risk prostate cancer (prostate-specific antigen <or=10, Gleason score <or=6, and clinical T1c/T2a) who underwent prostate brachytherapy using either 103Pd or 125I without supplemental external beam radiation therapy between October and December 1999. All patients underwent a transrectal ultrasound volumetric study of the prostate gland followed by the generation of a preplan based on a consistent, modified uniform seed-loading philosophy. The planning treatment volume (PTV) consisted of the prostate gland with approximately 5-mm anterior and lateral margins. The radiation dose was prescribed to the PTV with margin. Day 0 computed tomography-based dosimetric evaluation revealed an overall mean 100% isodose margin of 6.5 mm +/- 1.8 mm. For 125I and 103Pd, the 100% isodose margins were 6.8 mm +/- 1.6 mm and 6.3 mm +/- 1.9 mm, respectively. At the 90% and 75% isodose lines, the isodose margins differed by no more than 1 mm for the 2 isotopes. With the exception of the area near the bladder neck and the posterior border of the prostate, the 100% isodose margin was >or=5.0 mm for all slices evaluated. The utilization of preplanning periprostatic margins is strongly correlated with the administration of prescription radiation doses to the periprostatic region. The extent of the postimplant periprostatic margin (6.5 +/- 1.8 mm) satisfies the preplanning margin criterion of >5 mm.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528094     DOI: 10.1097/01.coc.0000091297.21810.fa

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  8 in total

1.  Evaluation of dosimetric margins in prostate IMRT treatment plans.

Authors:  J J Gordon; J V Siebers
Journal:  Med Phys       Date:  2008-02       Impact factor: 4.071

2.  Clinical research on the treatment effects of radioactive (125)I seeds interstitial brachytherapy on children with primary orbital rhabdomyosarcoma.

Authors:  Xin Ge; Jianmin Ma; Haojie Dai; Ling Ren; Quan Li; Jitong Shi
Journal:  Med Oncol       Date:  2014-08-05       Impact factor: 3.064

3.  Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy.

Authors:  Michael Dattoli; Kent Wallner; Lawrence True; David Bostwick; Jennifer Cash; Richard Sorace
Journal:  J Oncol       Date:  2010-08-18       Impact factor: 4.375

4.  Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.

Authors:  Andrew W Ju; Hongkun Wang; Eric K Oermann; Benjamin A Sherer; Sunghae Uhm; Viola J Chen; Arjun V Pendharkar; Heather N Hanscom; Joy S Kim; Siyuan Lei; Simeng Suy; John H Lynch; Anatoly Dritschilo; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-01-31       Impact factor: 3.481

5.  Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database.

Authors:  Gregory S Merrick; Wayne M Butler; Peter Grimm; Mallory Morris; Jonathan H Lief; Abbey Bennett; Ryan Fiano
Journal:  J Contemp Brachytherapy       Date:  2013-10-02

6.  Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment.

Authors:  Al V Taira; Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Ryan Fiano; Kent E Wallner; Edward Adamovich
Journal:  J Contemp Brachytherapy       Date:  2013-12-03

7.  Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts.

Authors:  Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Ryan Fiano; Edward Adamovich
Journal:  J Contemp Brachytherapy       Date:  2015-12-30

8.  Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers.

Authors:  Claire Meynard; Andres Huertas; Charles Dariane; Sandra Toublanc; Quentin Dubourg; Saik Urien; Marc-Olivier Timsit; Arnaud Méjean; Nicolas Thiounn; Philippe Giraud
Journal:  Radiat Oncol       Date:  2019-12-31       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.